Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Volagidemab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of GRA in Patients With Type 1
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study, which enrolled approximately 150 patients, is a randomized, placebo‑controlled study to evaluate the safety, efficacy, and pharmacodynamics of volagidemab at 35 mg and 70 mg in type 1 diabetes patients who are currently receiving insulin tre...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2019
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2017
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 22, 2016
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 27, 2015
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable